All In Biotech

Drug Trial Radar · NCT07643220

Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions

An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-G721" and "G721R" in Healthy Adult Male Subjects

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Jun 27, 2026

Primary completion

Jul 29, 2026

Study completion Jul 29, 2026

Sponsor

Lead sponsor
AJU Pharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 54 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.

Conditions

  • Moderate-to-severe Benign Prostatic Hyperplasia (BPH)

Interventions

  • Test DrugDrug

    AJU-G721

  • Reference DrugDrug

    G721R

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of Dutasteride and Tamsulosin.Time frame: [Time Frame: 0 hour ~ 72 hour after drug administration]
  2. AUCt of Dutasteride and TamsulosinTime frame: [Time Frame: 0 hour ~ 72 hour after drug administration]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bumin Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.